Faculty

Nancy Bartlett

MD
Professor of Medicine
Washington University

Dr. Bartlett is currently Professor of Medicine in the Department of Medicine at Washington University and holds the Koman Chair in Medical Oncology. She received a BS and MS in Chemical Engineering from Stanford University and MIT, respectively, and her MD from Washington University in St. Louis. Dr. Bartlett completed her internal medicine training at the University of California, San Francisco, where she also served as Chief Resident and her medical oncology fellowship at Stanford University. Her clinical research has focused on developing clinical trials to evaluate new therapies for lymphoma. She currently serves as Vice Chair of the Alliance Lymphoma Committee, a US cooperative group responsible for developing national clinical trials, and is a member of the NCI Lymphoma Steering Committee and the Lymphoma Research Foundation scientific advisory board. Dr. Bartlett has mentored several fellows and young faculty at Washington University and through the cooperative groups in clinical trial development. Dr. Bartlett serves as Chair of the Siteman Cancer Center Quality Assurance and Safety Monitoring Committee, supervising annual audits of all institutional cancer trials and reviewing semi-annual data and safety monitoring reports for these trials

2027 Sessions

Translating Evidence Into Action: A Case Discussion Panel in Lymphoma

Moderator

Panelist

Friday, February 05 4:40–5:30 PM
Room King Ballroom 3
Miami Regional Co-Chair

Alvaro Alencar

MD
Assistant Professor of Clinical Medicine
University of Miami Sylvester Comprehensive Cancer Center

Dr. Alencar is an Assistant Professor of Medicine member of the lymphoma program at the division of hematology at University of Miami Sylvester Comprehensive Cancer Center. Dr. Alencar is a national recognized expert in lymphoid malignancies. Over the last decade, he has focused his research on b-cell malignancies with a special interest in lymphoid malignancies in the elderly population. He also has a special interest on research of minorities and has worked extensively with multiple centers in Latin America on the research of genetic traits in hematologic disorders and correlation with ancestry. He is a member of the lymphoma committee at the Alliance for Clinical Trials in Oncology and is the principal investigator in several novel clinical trials at Sylvester Comprehensive Cancer Center.

LL&M Scientific Co-Chair

John Leonard

MD
Laura and Isaac Perlmutter Professor of Hematology and Medical Oncology, Chief of the Division of Hematology and Medical Oncology and Director, Center for Blood Cancers
NYU Langone Health and NYU Grossman School of Medicine

John P. Leonard, M.D., is the Laura and Isaac Perlmutter Professor of Hematology and Medical Oncology, Chief of the Division of Hematology and Medical Oncology and Director, Center for Blood Cancers at Perlmutter Cancer Center at NYU Langone Health and NYU Grossman School of Medicine.
An expert in hematology and oncology, Dr. Leonard is Chair of the Lymphoma Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB, ACOSOG and NCCTG), a multicenter cooperative group and key component of the National Cancer Institute’s National Clinical Trials Network. Dr. Leonard has been an elected member of the American Board of Internal Medicine Hematology subspecialty board, and he has also been elected to membership in the American Society of Clinical Investigation. He has served as Chair of the Scientific Advisory Board and Board Member of the Lymphoma Research Foundation and Board Member of the Leukemia and Lymphoma Society/New York City Chapter.
Dr. Leonard performed his undergraduate work at Johns Hopkins University and received his medical degree at the University of Virginia in Charlottesville, VA. He completed his residency in medicine at the New York Hospital - Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York, NY. He completed a fellowship in hematology and oncology at Cornell, and served as the chief medical resident at the New York Hospital - Cornell Medical Center.

Faculty

Juan Alderuccio

MD
Associate Professor of Medicine
Sylvester Comprehensive Cancer Center University of Miami

Dr. Juan Alderuccio is a clinical investigator specializing in lymphoma drug development at the University of Miami Sylvester Comprehensive Cancer Center, where he serves as Clinical Research Site Disease Group Leader of the Lymphoma Section and principal investigator on multiple clinical trials.
His research centers on designing innovative clinical trials and integrating circulating tumor DNA (ctDNA) into treatment decision-making for patients with indolent and aggressive B-cell lymphomas. He has been involved in the development of multiple investigator-initiated, NCI, and industry-supported clinical trials. Dr. Alderuccio's work has been supported by the Lymphoma Research Foundation, the US Department of Defense, and the American Society of Hematology Scholar Award.

Faculty

Nancy Bartlett

MD
Professor of Medicine
Washington University

Dr. Bartlett is currently Professor of Medicine in the Department of Medicine at Washington University and holds the Koman Chair in Medical Oncology. She received a BS and MS in Chemical Engineering from Stanford University and MIT, respectively, and her MD from Washington University in St. Louis. Dr. Bartlett completed her internal medicine training at the University of California, San Francisco, where she also served as Chief Resident and her medical oncology fellowship at Stanford University. Her clinical research has focused on developing clinical trials to evaluate new therapies for lymphoma. She currently serves as Vice Chair of the Alliance Lymphoma Committee, a US cooperative group responsible for developing national clinical trials, and is a member of the NCI Lymphoma Steering Committee and the Lymphoma Research Foundation scientific advisory board. Dr. Bartlett has mentored several fellows and young faculty at Washington University and through the cooperative groups in clinical trial development. Dr. Bartlett serves as Chair of the Siteman Cancer Center Quality Assurance and Safety Monitoring Committee, supervising annual audits of all institutional cancer trials and reviewing semi-annual data and safety monitoring reports for these trials

Faculty

Craig Moskowitz

MD
Physician-in-Chief, Oncology Service Line, Division of Hematology
Sylvester Comprehensive Cancer Center, University of Miami

Dr. Moskowitz is currently the Physician-in-Chief, Oncology Service Line at the SSylvester Comprehensive Cancer Center, part of the University of Miami Health System and Miller School of Medicine where he oversees cancer related clinical care, clinical research, faculty mentorship, Advanced Practice Providers as well as the Protocol Review and Monitoring Committee.
His academic career and research focus on improving the outcome of patients with poor risk Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL). This effort has been conducted along two tracks: 1) optimizing therapy for patients with relapsed and refractory disease, including high dose therapy (HDT) and autologous stem cell transplant (ASCT), CART approaches and studying new agents that can be incorporated into salvage therapy, and 2) developing risk-adapted strategies to optimize the treatment of newly diagnosed DLBCL and Hodgkin’s Lymphoma by using what we have learned in the relapsed and refractory setting.
This research has led to changes in standard of care that include the use of the most widely used salvage program ICE chemotherapy, PET-adapted therapies, maintenance therapy post-ASCT, utility of clinical and molecular-derived prognostic models in the relapsed and refractory setting, and the incorporation of novel immune-based approaches in the second-line setting.
Prior to coming to the Sylvester Comprehensive Cancer Centere, he practiced for 26 years at Memorial Sloan Kettering Cancer Center in New York, where he directed the division of Hematologic Oncology and had an endowed chair in lymphoma research.

Faculty

Sarah Rutherford

MD
Associate Professor of Medicine (Clinical)
NYU Langone Health

Dr. Sarah Rutherford is an Associate Professor of Medicine (Clinical) in the Division of Hematology/Oncology at NYU Langone Health. She is a graduate of the University of Virginia School of Medicine. She completed Internship and Residency in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia and Fellowship in Hematology/Oncology at New York-Presbyterian Hospital/Weill Cornell Medical College.

Dr. Rutherford has clinical expertise in lymphoma. Her research focuses on novel therapeutic strategies in B-cell and Hodgkin lymphomas. She has received honors from Weill Cornell Medical College and the American Society of Hematology, and support from the New York State Empire Clinical Research Investigator Program, the Lymphoma Research Foundation, the National Institutes of Health Clinical Loan Repayment Program, and the Alliance for Clinical Trials Foundation. She has experience in caring for patients with a variety of lymphomas and hematologic disorders including Hodgkin lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and peripheral T-cell lymphoma.

Mantle Cell Lymphoma Turns the Page on Transplant and Chemotherapy

Speaker

Saturday, February 06 8:55–9:15 AM
Room King Ballroom 3
Faculty

Nancy Bartlett

MD
Professor of Medicine
Washington University

Dr. Bartlett is currently Professor of Medicine in the Department of Medicine at Washington University and holds the Koman Chair in Medical Oncology. She received a BS and MS in Chemical Engineering from Stanford University and MIT, respectively, and her MD from Washington University in St. Louis. Dr. Bartlett completed her internal medicine training at the University of California, San Francisco, where she also served as Chief Resident and her medical oncology fellowship at Stanford University. Her clinical research has focused on developing clinical trials to evaluate new therapies for lymphoma. She currently serves as Vice Chair of the Alliance Lymphoma Committee, a US cooperative group responsible for developing national clinical trials, and is a member of the NCI Lymphoma Steering Committee and the Lymphoma Research Foundation scientific advisory board. Dr. Bartlett has mentored several fellows and young faculty at Washington University and through the cooperative groups in clinical trial development. Dr. Bartlett serves as Chair of the Siteman Cancer Center Quality Assurance and Safety Monitoring Committee, supervising annual audits of all institutional cancer trials and reviewing semi-annual data and safety monitoring reports for these trials

Q&A Panel

Moderator

Panelist

Saturday, February 06 9:35–9:45 AM
Room King Ballroom 3
Miami Regional Co-Chair

Alvaro Alencar

MD
Assistant Professor of Clinical Medicine
University of Miami Sylvester Comprehensive Cancer Center

Dr. Alencar is an Assistant Professor of Medicine member of the lymphoma program at the division of hematology at University of Miami Sylvester Comprehensive Cancer Center. Dr. Alencar is a national recognized expert in lymphoid malignancies. Over the last decade, he has focused his research on b-cell malignancies with a special interest in lymphoid malignancies in the elderly population. He also has a special interest on research of minorities and has worked extensively with multiple centers in Latin America on the research of genetic traits in hematologic disorders and correlation with ancestry. He is a member of the lymphoma committee at the Alliance for Clinical Trials in Oncology and is the principal investigator in several novel clinical trials at Sylvester Comprehensive Cancer Center.

Faculty

Nancy Bartlett

MD
Professor of Medicine
Washington University

Dr. Bartlett is currently Professor of Medicine in the Department of Medicine at Washington University and holds the Koman Chair in Medical Oncology. She received a BS and MS in Chemical Engineering from Stanford University and MIT, respectively, and her MD from Washington University in St. Louis. Dr. Bartlett completed her internal medicine training at the University of California, San Francisco, where she also served as Chief Resident and her medical oncology fellowship at Stanford University. Her clinical research has focused on developing clinical trials to evaluate new therapies for lymphoma. She currently serves as Vice Chair of the Alliance Lymphoma Committee, a US cooperative group responsible for developing national clinical trials, and is a member of the NCI Lymphoma Steering Committee and the Lymphoma Research Foundation scientific advisory board. Dr. Bartlett has mentored several fellows and young faculty at Washington University and through the cooperative groups in clinical trial development. Dr. Bartlett serves as Chair of the Siteman Cancer Center Quality Assurance and Safety Monitoring Committee, supervising annual audits of all institutional cancer trials and reviewing semi-annual data and safety monitoring reports for these trials

Faculty

Craig Moskowitz

MD
Physician-in-Chief, Oncology Service Line, Division of Hematology
Sylvester Comprehensive Cancer Center, University of Miami

Dr. Moskowitz is currently the Physician-in-Chief, Oncology Service Line at the SSylvester Comprehensive Cancer Center, part of the University of Miami Health System and Miller School of Medicine where he oversees cancer related clinical care, clinical research, faculty mentorship, Advanced Practice Providers as well as the Protocol Review and Monitoring Committee.
His academic career and research focus on improving the outcome of patients with poor risk Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL). This effort has been conducted along two tracks: 1) optimizing therapy for patients with relapsed and refractory disease, including high dose therapy (HDT) and autologous stem cell transplant (ASCT), CART approaches and studying new agents that can be incorporated into salvage therapy, and 2) developing risk-adapted strategies to optimize the treatment of newly diagnosed DLBCL and Hodgkin’s Lymphoma by using what we have learned in the relapsed and refractory setting.
This research has led to changes in standard of care that include the use of the most widely used salvage program ICE chemotherapy, PET-adapted therapies, maintenance therapy post-ASCT, utility of clinical and molecular-derived prognostic models in the relapsed and refractory setting, and the incorporation of novel immune-based approaches in the second-line setting.
Prior to coming to the Sylvester Comprehensive Cancer Centere, he practiced for 26 years at Memorial Sloan Kettering Cancer Center in New York, where he directed the division of Hematologic Oncology and had an endowed chair in lymphoma research.

Faculty

Sarah Rutherford

MD
Associate Professor of Medicine (Clinical)
NYU Langone Health

Dr. Sarah Rutherford is an Associate Professor of Medicine (Clinical) in the Division of Hematology/Oncology at NYU Langone Health. She is a graduate of the University of Virginia School of Medicine. She completed Internship and Residency in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia and Fellowship in Hematology/Oncology at New York-Presbyterian Hospital/Weill Cornell Medical College.

Dr. Rutherford has clinical expertise in lymphoma. Her research focuses on novel therapeutic strategies in B-cell and Hodgkin lymphomas. She has received honors from Weill Cornell Medical College and the American Society of Hematology, and support from the New York State Empire Clinical Research Investigator Program, the Lymphoma Research Foundation, the National Institutes of Health Clinical Loan Repayment Program, and the Alliance for Clinical Trials Foundation. She has experience in caring for patients with a variety of lymphomas and hematologic disorders including Hodgkin lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and peripheral T-cell lymphoma.

Back to top